Goodbye Malaria is an initiative started by African entrepreneurs who believe that today’s generation can create innovative solutions to the continent’s problems and ultimately change the way the world sees Africa. Since the turn of the century, vector control has proven to be one of the most effective strategies for reducing malaria incidence and deaths. Since 2000, more than 80% of the reduction in malaria prevalence in Africa can be attributed to indoor residual spraying (IRS) and insecticide-treated nets (ITNs).
Traditionally, men have been responsible for implementing IRS in sub-Saharan Africa. However, this traditional view is increasingly being challenged as more organisations recognize that women should play a more significant role in conducting and leading spray operations.Zero by 40 summary 28th April 2022
Envisioning insecticide resistance management and integrated vector management a ZERO by 40 perspective.Zero by 40 full report 28th April 2022
Envisioning insecticide resistance management and integrated vector management a ZERO by 40 perspective.Multi-site comparison of factors influencing progress of African insecticide testing facilities towards an international Quality Management System certification 6th December 2021
Insecticidal mosquito vector control products are vital components of malaria control programmes. Test facilities are key in assessing the effectiveness of vector control products against local mosquito populations, in environments where they will be used. Data from these test facilities must be of a high quality to be accepted by regulatory authorities, including the WHO Prequalification Team for vector control products. In 2013–4, seven insecticide testing facilities across sub-Saharan Africa, with technical and financial support from Innovative Vector Control Consortium (IVCC), began development and implementation of quality management system compliant with the principles of Good Laboratory Practice (GLP) to improve data quality and reliability.Accelerating Global Health R&D 24th May 2021
This study assesses development of new medicines and technologies for 35 poverty-related and neglected diseases, including HIV/AIDS, malaria and tuberculosis. The findings and recommendations will help shape future investments and activities in this field for the UK government and other major government donors and philanthropies.